CATALYST FOR CHANGE
BIOSIMILARS
02.
OVERCOMING ROADBLOCKS TO EXPAND ACCESS
biosimilar medicines represent a rapidly emerging field that can offer improved accessibility to medicines for patients at reduced expenditure for healthcare systems that are tackling issues of sustainability. with a majority of monoclonal antibodies [mAbs] and novel biologic therapies coming off patent by 2020, the number of biosimilars in development has exploded, creating a new playing field important for all stakeholders. biosimilars uptake in oncology can positively impact the financial burden of healthcare systems with the cost savings being reallocated to improve overall health system outcomes, globally. this presents an opportunity for physicians, patients, and payors to gain the most benefit from increased access to life saving therapies.

public payors are looking to improve efficiency of processes, prioritization of drugs, cost containment of cancer care and increase access to innovative medicines. championing a strong biosimilar market in canada through policies that encourage uptake, ongoing education for key stakeholders along with the concept of gainsharing, in which cost savings from the use of biosimilars are reallocated to improve overall health system outcomes, will be beneficial to all stakeholders.

biosimilar pegfilgrastim. improving access and optimising practice to supportive care that enables cure
biosimilar pegfilgrastim offers countries using biosimilar filgrastim opportunities to improve adherence and thus cancer survival, whilst offering economic benefits for countries using reference pegfilgrastim. these benefits can be realised in full if biosimilar pegfilgrastim becomes part of routine clinical practice supported by drug and therapeutic committees implementing guidelines with multidisciplinary support in the hospital.
march 2020
biosimilar medicines can significantly reshape access to innovative cancer therapies. infographic
as breakthrough discoveries and novel treatments continue to dominate research in oncology and the escalating cost of cancer care placing an increasing burden on healthcare systems,  we are being faced with increasing sustainability issues.  biosimilars offer the potential of greater choice and value, increased patient access to treatment, and the potential for improved outcomes while creating efficiency and cost savings to already overstretched drug budgets.  because they have an opportunity to provide competition in the market and expand patient access to critical medicines by allowing cost savings to be reinvested into access to innovative medicines, earlier and improve patient care – providing better value for money for healthcare budgets.

colab.february 2020

CADTH technology 360 review. optimal use report
utilization of innovator biologics and biosimilars for chronic inflammatory diseases in canada. a provincial perspective
CADTH technology review. optimal use 360 report

january 2020
biosimilar drugs to provide safe, effective treatment
alberta’s policy expanding the use of biosimilar prescription drugs will save hundreds of millions of dollars while providing the same safe, effective treatment
shifting biosimilar access policies to promote fiscal sustainability in the canadian healthcare system
the original wave of biosimilar regulatory approvals in Canada several years ago prompted a range of reimbursement policy responses on the part of both public and private payers. canadian public payers leveraged introduction of the infliximab biosimilar to create policies intended to secure significant cost savings for drug plans as the scope of available biosimilars expanded over time.
medicines for europe. position statements on physician led switching for biosimilars [EU]
september 2019
biosimilars regulation in canada. state of play
november 2019
an ever evolving landscape. an update on the rapidly changing regulation and reimbursement of biosimilars in canada
august 2019
siu cke., tomalin a., et al.
position of scientific oncological societies towards biosimilars
february 2019
wörmann b. · sinn m.
biosimilars in canada. current and future opportunities
april 2019
PMPRB report on biosimilars in canada – current and future opportunities
advancing biosimilar sustainability in europe- IQVIA Report
04 sept 2018
A Multi-Stakeholder Assessment
IQVIA Institute Report
colab webinar series : biosimilars. the european experience
europe has lead the way in the uptake of biosimilars in the oncology landscape, what learnings and best practices can we learn from their experience as we begin to introduce biosimilars into the canadian context. a discussion that will focus on the practical application of biosimilars in oncology from the european perspective, what worked, what learnings were had and what could this look like in canada.

payor perspective
June 19, 2019 11:00 am in eastern time (US and Canada)
View recorded webinar

policy perspective
details for registration coming shortly

health care provider perspective
details for registration coming shortly

CADTH program updates on biosimilars
biosimilars will no longer be reviewed through the CADTH CDR and pCODR processes.
as of june 1, 2019, CADTH will be stopping work on any biosimilar reviews that would have been completed after june 1, 2019.
update : cadth pharmaceutical review- issue 8
breast cancer & biosimilars from the canadian breast cancer network
recommendations on use, implementation and patient communications
access whitepaper
pan-canadian oncology biosimilars initiative
an initiative that is part of the pan-canadian pharmaceutical alliance’s biosimilars strategy.

this biosimilars initiative aims to ensure that the implementation and use of therapeutic oncology biosimilars are appropriate and cost-effective across canada and is jointly supported by the pan-canadian pharmaceutical alliance and managed by cancer care ontario on behalf of all provincial cancer agencies.
website link

map for implementing oncology biosimilars across canada.
biosimilars action report

biosimilar biologic drugs in canada. fact sheet health canada
a biosimilar is a biologic drug that is highly similar to a biologic drug that was already authorized for sale. there are no expected clinically meaningful differences in efficacy and safety between a biosimilar and the biologic drug that was already authorized for sale.

health canada authorizes biosimilars for sale using the same rigorous regulatory standards for quality, efficacy and safety as for all other biologic drugs.

biosimilars fact sheet 

the cancer collaborative biosimilars initiative is supported with funding by the following organizations

cancercolab

we can be the catalyst for change.
fostering an environment of co-creation & collaboration to make action-oriented changes in cancer care in canada.

CONTACT US

hello@cancercolab.ca

#cancercolab
#travelwithcolab